Health Care [ 8/12 ] | Biotechnology [ 51/73 ]
NASDAQ | Common Stock
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II.
It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease.
In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies.
Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States.
REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 25 | -1.38 Decreased by -31.43% | -0.94 Decreased by -46.81% |
| May 6, 25 | 0.12 Increased by +109.02% | 0.49 Decreased by -75.29% |
| Feb 25, 25 | -1.01 Increased by +29.37% | -1.08 Increased by +6.86% |
| Nov 6, 24 | -1.17 Increased by +17.02% | -1.12 Decreased by -4.46% |
| Aug 1, 24 | -1.05 Increased by +36.75% | -1.29 Increased by +18.60% |
| May 8, 24 | -1.33 Increased by +13.07% | -1.26 Decreased by -5.56% |
| Feb 27, 24 | -1.43 Decreased by -3.62% | -1.27 Decreased by -12.60% |
| Nov 8, 23 | -1.41 Increased by +19.43% | -1.52 Increased by +7.24% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 21.36 M Decreased by -4.20% | -70.87 M Decreased by -33.75% | Decreased by -331.81% Decreased by -39.61% |
| Mar 31, 25 | 89.01 M Increased by +469.79% | 6.08 M Increased by +109.61% | Increased by +6.83% Increased by +101.69% |
| Dec 31, 24 | 21.21 M Decreased by -4.50% | -51.19 M Increased by +18.61% | Decreased by -241.28% Increased by +14.78% |
| Sep 30, 24 | 24.20 M Decreased by -16.31% | -59.60 M Increased by +3.67% | Decreased by -246.30% Decreased by -15.11% |
| Jun 30, 24 | 22.30 M Increased by +11.60% | -52.99 M Increased by +26.47% | Decreased by -237.67% Increased by +34.11% |
| Mar 31, 24 | 15.62 M Decreased by -18.37% | -63.33 M Increased by +9.46% | Decreased by -405.39% Decreased by -10.91% |
| Dec 31, 23 | 22.21 M Decreased by -29.13% | -62.89 M Decreased by -4.93% | Decreased by -283.12% Decreased by -48.07% |
| Sep 30, 23 | 28.91 M Increased by +9.06% | -61.87 M Increased by +22.59% | Decreased by -213.97% Increased by +29.02% |